# Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

> **NCT06041919** · PHASE2 · TERMINATED · sponsor: **Thirty Respiratory Limited** · enrollment: 20 (actual)

## Conditions studied

- Rifampicin Susceptible Pulmonary Tuberculosis

## Interventions

- **DRUG:** RESP301
- **DRUG:** HRZE

## Key facts

- **NCT ID:** NCT06041919
- **Lead sponsor:** Thirty Respiratory Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-27
- **Primary completion:** 2024-07-24
- **Final completion:** 2025-03-06
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Decision was made by the sponsor not to progress to Stage 2
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041919, "Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06041919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*